1993~

Breaking away from a crisis and creating value

Tsumura, which had fallen into a crisis situation, appointed a president from outside the company for the first time in 1995 and started measures to improve its management, including reducing interest-bearing debt and divesting subsidiaries.
Tsumura also worked to restructure the sales organization and promote and establish Kampo medicine. In the fiscal year ended March 31, 2004, Tsumura resumed dividend payments, coming back from the brink.
Since then, Tsumura has taken various measures to promote Kampo medicine, including “ikuyaku” or post-marketing drug rearing to establish scientific evidence for Kampo medicine, creating a crude drug traceability system, expanding Kampo medicine internationally, and establishing Yubari Tsumura and Lao Tsumura.

  • 1993

    100th anniversary

    Tsumura held an International Kampo Symposium to commemorate the 100th anniversary of the company.

  • 1999

    Kampo medicine seminars started

    Kampo medicine seminars (introductory course) started.

  • 2001

    Shanghai Tsumura Pharmaceuticals Co., Ltd. established

    Shanghai Tsumura Pharmaceuticals Co., Ltd. was established as a manufacturing base for extract powder (intermediate products) in China.

  • 2004

    Promotion of ikuyaku (post-marketing drug rearing)

    Tsumura changed the R&D policy to specialize in Kampo and crude drugs and promote ikuyaku (post-marketing drug rearing).

  • 2007

    Head office relocated

    The head office was moved from Nibancho, Chiyoda-ku to Akasaka, Minato-ku.

  • 2009

    Yubari Tsumura established

    A subsidiary, Yubari Tsumura Co., Ltd., was established to oversee the crude drugs business in Hokkaido.

  • 2010

    Lao Tsumura established

    Lao Tsumura Co., Ltd. was established as a base for the cultivation, procurement, preparation and processing, and storage of crude drug ingredients in Laos.

  • 2015

    Packaging design changed

    New bar code labelling was adopted and packaging designs for prescription drugs were changed.

  • 2018

    Established a Joint Venture with Ping An Insurance (China)

    Established a joint venture with Ping An Insurance (Group) Company of China, Ltd.

    Establishment of TIANJIN TSUMURA PHARMACEUTICALS CO., LTD.

    TIANJIN TSUMURA Pharmaceuticals Co., Ltd. was established as a manufacturing base for extract powder (intermediate products) in China.

  • 2022

    Establishment of the Purpose and Formulation of TSUMURA VISION “Cho-WA” 2031

    The TSUMURA Group established its Purpose and formulated its long-term management vision, TSUMURA VISION “Cho-WA” 2031, defining a new management direction aimed at contributing to people's well-being.

  • 2026

    YOMEISHU SEIZO CO., LTD. joined the TSUMURA Group

    YOMEISHU SEIZO CO., LTD. joined the TSUMURA Group, marking a new step toward contributing to richer lives through health and self-care by leveraging the strengths of both companies.

Related pages

About TSUMURA